Quantified Imaging Limited secures £246.4k pre-seed to advance MRI software for brain disorders

Quantified Imaging Limited, a London-based biotechnology and health tech startup, has raised £246.4k in a pre-seed funding round. The investment gives the early-stage company an estimated post-money valuation of £2.2m.

Founded in March 2023, Quantified Imaging develops advanced MRI analysis software designed to improve the assessment of neurological conditions. The company utilises non-invasive arterial spin labeling (ASL) and chemical exchange saturation transfer (CEST) techniques to extract quantitative insights into brain disorders, with a particular focus on dementia and traumatic brain injury.

The startup provides its proprietary software tools to clinicians, hospitals, and clinical trials. By measuring physiological markers such as blood flow without the need for invasive procedures, the technology aims to facilitate earlier diagnosis, improve treatment monitoring, and accelerate clinical trials for neurodegenerative diseases.

Currently operating with a core team of between four and seven employees, Quantified Imaging remains in its critical research and development phase. Financial metrics such as revenue and profit are not yet publicly available for the early-stage company.

The pre-seed funding round saw the company allot shares on June 30, 2025, with the official filing registered on January 19, 2026. The £246.4k injection values the business at £2.2m post-money. While the specific venture capital investors backing this equity round have not been publicly disclosed, the company has previously secured non-dilutive capital to support its research. This includes a £360k grant awarded through the UK government Dame Barbara Windsor Dementia Mission, as well as backing from Innovate UK.

This early-stage investment fits into a broader, highly selective funding landscape for UK life sciences. According to the BioIndustry Association, UK biotech companies raised £1.79bn in venture capital in 2025, representing a 13.2 percent year-on-year decrease. Deal volume also dropped, with capital increasingly concentrated into a smaller number of large, later-stage rounds.

Despite the tighter macroeconomic environment, the UK retained its position as the leading national biotech market in Europe in 2025, capturing 30 percent of all European venture financing. Startups operating at the intersection of software and clinical diagnostics continue to attract targeted investment, particularly those addressing high-burden conditions like Alzheimer disease and dementia. The successful pre-seed raise by Quantified Imaging highlights ongoing investor appetite for foundational medical technologies that can demonstrate clear clinical utility.